

Infections in Acute Variceal Bleeding and Role of Antibiotics

Rerknimitr R

Epidemiology

Due to several defective in bacterial defense mechanisms, cirrhotic patients are susceptible to bacterial infections. The most common infections are spontaneous bacterial peritonitis (23-32%), urinary tract infection (10-41%), pneumonia (17-21%) and bacteremia (13-21%)⁽¹⁻⁴⁾. Majority of infections involved in a single site⁽³⁾, gram negative bacteria especially *Escherichia coli* being the most common pathogen detected⁽³⁾. Apart from impairment of the reticuloendothelial system, small bowel dysmotility, bacterial overgrowth in the small intestine, and increased intestinal permeability in cirrhosis⁽⁵⁾, variceal bleeding has been reported as an independent factor for bacterial infection^(1,2,6). Husová, *et al* reported a higher rate of bacterial infection among patients with acute portal hypertensive related bleeding (25 of 35 patients, 71%) than among patients with liver cirrhosis and portal hypertension without acute bleeding (14 of 35 patients, 40%, $p < 0.01$). Various tubes insertion (NG, CVP, endotracheal and Senstagen-Blakemore) causing infections has been concerned as another important factor. Gastric content refluxation as an endogenous source for bacterial colonization of ventilator tubing systems was demonstrated from a surveillance study in patients who admitted in the intensive care unit⁽⁷⁾. One of the well known infections related to Senstaken-Blakemore tube insertion is the development of aspiration pneumonia after prolonged tube insertion⁽⁸⁾. To date, there has been no direct study comparing the risk from these tubes causing infection in variceal bleeders.

Prophylactic antibiotics and risk of infection, mortality and rebleeding

The routine investigation to detect early infection nowadays in patients who present with variceal bleeding includes a complete blood count, urine analysis. A chest X-ray, abdominal paracentesis, throat culture, and hemoculture are indicated in selected patients. In a prospective surveillance study, Lata *et al* demonstrated a higher rate of positive blood and throat cultures in bleeders than controls⁽⁹⁾.

Since anaerobic bacteria has been known to maintain gut resistance against intestinal colonization, overgrowth, and extra-intestinal spread of pathogens⁽¹⁰⁾, then selective intestinal decontamination by eradicating gram negative bacteria and preserving anaerobic flora has been suggested as a method of preventing bacterial infections in these patients. A meta-analysis from 19 randomized controlled trials, without heterogeneity, showed the beneficial effect of prophylactic antibiotics in reducing mortality (RR: 0.70; 95% CI: 0.56, 0.89) and prevention of bacterial infection (RR: 0.39; 95% CI: 0.32, 0.48) for cirrhotic. Patients who admitted in the hospital⁽¹¹⁾. When focusing in the group with gastrointestinal bleeding, prophylactic antibiotics play important roles in reducing mortality (RR 0.73, 95% CI 0.55 to 0.95) and the incidence of bacterial infections (RR 0.40, 95% CI 0.32 to 0.51) significantly⁽¹²⁾. The same meta-analysis⁽¹²⁾ also reported no significant efficacy of the individual antibiotic regimens versus placebo/no intervention on the survival rate (quinolones: RR 0.73, 95% CI 0.46 to 1.15;

quinolones + amoxicillin/clavulonic acid: RR 0.74, 95% CI 0.42 to 1.31; other antibiotic regimens: RR 0.72, 95% CI 0.48, 1.08). Moreover, all regimens provided significant results over the placebo/no intervention regarding the incidence of bacterial infections (quinolones: RR 0.30, 95% CI 0.20 to 0.46; quinolones + amoxicillin/clavulonic acid: RR 0.38, 95% CI 0.23 to 0.62; other antibiotic regimens: RR 0.53, 95% CI 0.38, 0.75). Comparing to on demand antibiotic treatment, a study from Taiwan⁽¹³⁾ has shown that antibiotic prophylaxis can prevent infection and rebleeding as well as decrease the amount of blood transfused for acute variceal bleeding. In addition, early rebleeding within 7 days reduced significantly (4/12 vs. 21/27, $p = 0.0221$). The relative hazard of rebleeding within 7 days was 5.078 (95% CI: 1.854-13.908, $p < 0.0001$). Likewise in a study with the use of an intravenous cefotaxime, June *et al* reported that the actuarial rebleeding rate in patients who received prophylactic antibiotic was significantly lower than that in the on-demand group (33.9% vs 62.1%, $p = 0.004$)⁽¹⁴⁾. Currently, there is no consensus on the choice of antibiotic for this situation, oral quinolones and intravenous cephalosporins as a single agent or in a combination have been used in many trials⁽¹⁵⁻¹⁸⁾. However, in the era of high incidence of infections caused by quinolone-resistant organism, a recently study from Barcelona demonstrated that 7 days intravenous ceftriaxone was better than oral norfloxacin for prevention of possible infections, proved infections, and spontaneous bacteremia or spontaneous bacterial peritonitis (11% vs 33%, $p = 0.003$; 11% vs 26%, $p = 0.03$; and 2% vs 12%, $p = 0.03$, respectively)⁽¹⁹⁾. In Asian-Pacific countries where quinolones have been used widely, the possibility of quinolones failure to prevent infection, rebleeding rate and decreasing mortality has to be kept in mind.

Risk of infection in elective endoscopy for esophageal and gastric varices

Although, elective sclerotherapy and band ligation for esophageal varices (EV) have been reported to be associated with transient bacteremia in 2-12% of cirrhotic patients⁽²⁰⁻²⁴⁾, the reported risk of clinical infection was insignificant. Gram-positive oral flora were mostly identified from blood cultures, In contrast, patients who developed clinical significant peritonitis, gram negative bacilli were identified and these were not correspondent to the results of blood cultures⁽²⁴⁾. Elective injection of gastric varices (GV) with cy-

anoacrylate has been accepted as a common practice worldwide to further obliterate GV. The risk of bacteremia from cyanoacrylate injection for GV was only found during the emergency endoscopy⁽²⁵⁾. By contrast, in an elective setting, the risk of bacteremia was reported as zero⁽²⁶⁾. It is speculate that the bacteremia develops from ruptured variceal membrane. In addition, gastric acidity and pepsin possibly reduce the number of organism in the stomach of patient undergoing elective GV injection⁽²⁷⁾. Moreover, a significant protective effect of bacterial invasion by cyanoacrylate has been shown in vitro studies^(28,29).

Consensus statements

1) Acute variceal bleeding contains a significant risk for bacterial infections (1b, A), and prophylactic antibiotic is recommended (1a, A).

2) Antibiotics have been proven to prevent bacterial infection (1a, A), to reduce mortality (1a, A) and rebleeding rates in cirrhotics with acute bleeding (1b, A).

3) Intravenous cephalosporin is preferred over oral quinolone for prophylaxis against infection, bacteremia and spontaneous bacterial peritonitis (1b, A).

4) Risk of significant infection in elective sclerotherapy and variceal ligation for esophageal and gastric varices is low, therefore prophylactic antibiotic may not be necessary (1b, A).

REFERENCES

1. Deschènes M, Villeneuve JP. Risk factors for the development of bacterial infections in hospitalized patients with cirrhosis. *Am J Gastroenterol* 1999;94:2193-7.
2. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. *J Hepatol* 1993;18:353-8.
3. Borzio M, Salerno F, Piantoni L, *et al*. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. *Dig Liver Dis* 2001;33:41-8.
4. Almeida D, Lopes AA, Santos-Jesus R, *et al*. Comparative study of bacterial infection prevalence between cirrhotic patients with and without upper gastrointestinal bleeding. *Braz J Infect Dis* 2001;5:136-42.
5. Thalheimer U, Triantos CK, Samonakis DN, *et al*. Infection, coagulation, and variceal bleeding in cirrhosis. *Gut* 2005;54:556-63.
6. Husová L, Lata J, Husa P, *et al*. Bacterial infection and acute bleeding from upper gastrointestinal tract in patients with liver cirrhosis. *Hepatogastroenterology* 2005;52:1488-90.

7. Inglis TJ, Lim EW, Lee GS, *et al.* Endogenous source of bacteria in tracheal tube and proximal ventilator breathing system in intensive care patients. *Br J Anaesth* 1998;80:41-5.
8. Chojkier M, Conn HO. Esophageal tamponade in the treatment of bleeding varices. A decadel progress report. *Dig Dis Sci* 1980;25:267-72.
9. Lata J, Juránková J, Husová L, *et al.* Variceal bleeding in portal hypertension: bacterial infection and comparison of efficacy of intravenous and per-oral application of antibiotics—a randomized trial. *Eur J Gastroenterol Hepatol* 2005;17:1105-10.
10. Arroyo V, Navasa M, Rimola A. Spontaneous bacterial peritonitis in liver cirrhosis: treatment and prophylaxis. *Infection* 1994;22 (Suppl 3):167-75.
11. Soares-Weiser K, Brezis M, Tur-Kaspa R, *et al.* Antibiotic prophylaxis of bacterial infections in cirrhotic inpatients: a meta-analysis of randomized controlled trials. *Scand J Gastroenterol* 2003;38:193-200.
12. Soares-Weiser K, Brezis M, Tur-Kaspa R, *et al.* Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding. *Cochrane Database Syst Rev* 2002;(2):CD002907.
13. Hou MC, Lin HC, Liu TT, *et al.* Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. *Hepatology* 2004;39:746-53.
14. Jun CH, Park CH, Lee WS, *et al.* Antibiotic prophylaxis using third generation cephalosporins can reduce the risk of early rebleeding in the first acute gastroesophageal variceal hemorrhage: a prospective randomized study. *J Korean Med Sci* 2006;21:883-90.
15. Soriano G, Guarner C, Tomás A, *et al.* Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. *Gastroenterology* 1992;103:1267-72.
16. Selby WS, Norton ID, Pokorny CS, *et al.* Bacteremia and bacterascites after endoscopic sclerotherapy for bleeding esophageal varices and prevention by intravenous cefotaxime: a randomized trial. *Gastrointest Endosc* 1994; 40:680-4.
17. Sábat M, Kolle L, Soriano G, *et al.* Parenteral antibiotic prophylaxis of bacterial infections does not improve cost-efficiency of oral norfloxacin in cirrhotic patients with gastrointestinal bleeding. *Am J Gastroenterol* 1998;93:2457-62.
18. Hsieh WJ, Lin HC, Hwang SJ, *et al.* The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding. *Am J Gastroenterol* 1998;93:962-6
19. Fernández J, Ruiz del Arbol L, Gómez C, *et al.* Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. *Gastroenterology* 2006; 131:1049-56.
20. Lorgat F, Madden MV, Kew G, *et al.* Bacteremia after injection of esophageal varices. *Surg Endosc* 1990;4:18-9.
21. Camara DS, Gruber M, Barde CJ, *et al.* Transient bacteremia following endoscopic injection sclerotherapy of esophageal varices. *Arch Intern Med* 1983;143:1350-2.
22. Cohen LB, Korsten MA, Scherl EJ, *et al.* Bacteremia after endoscopic injection sclerosis. *Gastrointest Endosc* 1983;29: 198-200.
23. da Silveira Rohr MR, Siqueira ES, Brant CQ, *et al.* Prospective study of bacteremia rate after elastic band ligation and sclerotherapy of esophageal varices in patients with hepatosplenic schistosomiasis. *Gastrointest Endosc* 1997;46:321-3.
24. Lin OS, Wu SS, Chen YY, *et al.* Bacterial peritonitis after elective endoscopic variceal ligation: a prospective study. *Am J Gastroenterol* 2000;95:214-7.
25. Chen WC, Hou MC, Lin HC, *et al.* Bacteremia after endoscopic injection of N-butyl-2-cyanoacrylate for gastric variceal bleeding. *Gastrointest Endosc* 2001;54:214-8.
26. Rerknimitr R, Chanyaswad J, Kongkam P, *et al.* Risk of bacteremia in bleeding and nonbleeding gastric varices after endoscopic injection of cyanoacrylate. *Endoscopy* 2008;40:644-9
27. Hao WL, Lee YK. Microflora of the gastrointestinal tract: a review. *Methods Mol Biol* 2004; 268:491-502.
28. Fenzl TC, Fenzl RE, Harris L. Antimicrobial properties of alkyl-2-cyanoacrylate tissue adhesives in vitro. *Am J Ophthalmol* 1983;95:125-6.
29. Eiferman RA, Snyder JW. Antibacterial effect of cyanoacrylate glue. *Arch Ophthalmol* 1983;101:958-60.